NTL builds a healthier world
NTL builds a healthier world.
NTL is specializing in female cancer which creates healthy future.
In 1996, NTL supplied ‘Cervicography’, an analogue cervical cancer reading system, for the first time in Korea. Since then, by developing the world’s first remote uterine cervical cancer readout reading system, NTL has made a significant contribution to lowering the incidence of cervical cancer.
We provide cervical cancer diagnosis services to improve the quality of life of women around the world.
Furthermore, we are creating advanced technology for diagnosing women’s diseases based on AI(artificial intelligence) by connecting healthcare, technology and people.
NTL creates a healthy tomorrow for a world where all women can be free from cervical cancer, regardless of borders and regions
Hello
Beyond being the first in Korea, we feel both pride and responsibility in leading the cervical cancer diagnosis market under the catchphrase Global No. 1. The recently developed CerviCARE® AI platform enables on-site real-time cervical cancer diagnosis. It is easy and convenient to use even in countries with insufficient medical infrastructure. We have been focusing a lot of time on cervical cancer diagnosis.
In the future, NTL’s efforts will not stop until the day women around the world who can be someone’s mother, daughter, or family become safe from cervical cancer.
Taehee Kim, CEO of NTL Healthcare
History of NTL,
growing company
2024
- Introducing ‘Dr.CerviCARE’ a remote cervical cancer screening device
- Introducing ‘iner:y NK’ a feminine cleanser containing NK cell culture extract
- Publication on Improving early detection of cervical cancer using AI
- Joins the US Cancer Moonshot Project ‘Cancer X’ as a member
- Expand into the Indian Market with CerviCARE AI at MFI (: Medical Fair India)
- Expand into the Brazillian Market with CerviCARE AI at the Federal University Hospital in Sao Paulo
- Establishes Joint Venture with ‘NTD Healthcare’ in Ho Chi Minh, Vietnam
- Collaborates with Costa Rica’s Micitt and the NIPA on AI Research
2023
- Released CerviCARE® AI, an artificial intelligence-based cervical cancer diagnosis assisting system
- Currently, services are being provided to about 1,500 obstetrics and gynecology clinics, examination centers, university hospitals and etc. at home and abroad.
2022
- Established the reading system with Artificial Intelligence (AI) and Collective Intelligence (CI) combined
- Released the medical camera Dr. Cervicam® C20 Plus for uterine cervical imaging
- Had AI Medical Software CerviCARE® AI Classe 3 approved by the Korea Ministry of Food and Drug Safetyy
- Signed an exclusive distribution contract with Prodizen of ‘PRS PRP’ for obstetrics and gynecology
- Participated in the Arab Health International Medical Device Exhibition (Dubai)
2021
- Developed the AI diagnostic system for cervical cancer
- Signed an exclusive distribution contract with Huons Meditech of ‘JILL’SOF™’ for Obstetrics and Gynecology
- Signed an exclusive distribution contract with Cardinal Health for “SCD Sleeve” for obstetrics and gynecology
- Got the certification of a Youth-friendly, good company selected by the Ministry of Employment and Labor
- Released Dr. Cervicam® C20 cervical imaging medical camera
2020
- Participated in the Arab Health International Medical Device Exhibition (Dubai)
- National tour symposium for the Korean Association of Obstetricians and Gynecologists (seven times for main sponsorship and lecture)
2019
- Participated in the Arab Health International Medical Device Exhibition (Dubai)
- National tour symposium for the Korean Association of Obstetricians and Gynecologists (eight times for main sponsorship and lecture)
- Conducted the performance improvement project for Korean promising medical devices organized by the Korea Health Industry Development Institute
- Conducted a technology-based start-up-type project organized by the Ministry of SMEs and Startups
2018
- National tour symposium for the Korean Association of Obstetricians and Gynecologists (sixteen times for main sponsorship and lecture)
- Received the achievement award from the Korean Association of Obstetricians and Gynecologists
- Received the grand prize in the bio category of the Korea Industry Grand Prize
2017
- Participated in American Society of Cervical Cancer & Pathology and American Cancer Society seminars
- Introduced endometrial cancer screening test in Korea; marketing first in Korea
2015
- Exported digital Cervicography: Mongolia
2014
- Developed the world’s first wireless uterine cervical cancer screening system
- Exported a digital Cervicography equipment: Bangladesh, Thailand, Saudi Arabia
2013
- Conducted an invited lecture at the Vietnam-France Obstetrics and Gynecology Society (Hanoi)
- Established a company-affiliated research institute
2011
- Selected as a patent star company
2010
- Designated as a promising export enterprise
- Certified as a KOTRA guaranteed brand
- Developed the world’s first wireless Cervicography
2009
- Exported digital Cervicography equipment: Czech Republic, India
2008
- Received a commendation from the Minister of Knowledge Economy
2007
- Localized Cervicography equipment
- Certified as a venture business
- Certified as a technology innovation enterprise (INNO-BIZ)
- Received certification from FDA and CE
- Selected as a World-class Product (Ministry of Trade, Industry and Energy)
2006
- American Society of Cervical Cancer & Pathology
2003
- Developed the world’s first web-based Cervicography (TeleCervico) system
1999
- Localized analogue Cervicography equipment
1997
- Selected in the cancer conquest project organized by the Ministry of Health and Welfare
- Established the Korea Cervicography Research Society
1996
- Established NTL Healthcare Co., Ltd.
- Designated as the exclusive agent of the US cervical magnification imaging and reading (Cervicography) system in Korea
NTL Healthcare Co., Ltd.
ADD
(13449) #710-713, 42, Changeop-ro,
Sujeong-gu, Seongnam-si,
Gyeonggi-do, Republic of Korea
TEL
+82-2-401-7799
FAX
+82-2-400-4711
guest@ntllab.com
